oxytocin Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
oxytocin derivatives	2042	50-56-6

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: oxytocin orasthin oxystin partocon perlacton synthetic oxytocin	A nonapeptide hormone released from the neurohypophysis (PITUITARY GLAND, POSTERIOR). It differs from VASOPRESSIN by two amino acids at residues 3 and 8. Oxytocin acts on SMOOTH MUSCLE CELLS, such as causing UTERINE CONTRACTIONS and MILK EJECTION. Molecular weight: 1007.19 Formula: C43H66N12O12S2 CLOGP: -0.65 LIPINSKI: 3 HAC: 24 HDO: 12 TPSA: 399.53 ALOGS: -4.26 ROTB: 17 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

oxytocin
orasthin
oxystin
partocon
perlacton
synthetic oxytocin

A nonapeptide hormone released from the neurohypophysis (PITUITARY GLAND, POSTERIOR). It differs from VASOPRESSIN by two amino acids at residues 3 and 8. Oxytocin acts on SMOOTH MUSCLE CELLS, such as causing UTERINE CONTRACTIONS and MILK EJECTION.

Molecular weight: 1007.19
Formula: C43H66N12O12S2
CLOGP: -0.65
LIPINSKI: 3
HAC: 24
HDO: 12
TPSA: 399.53
ALOGS: -4.26
ROTB: 17

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

Dose	Unit	Route
15	U	N
200	U	O
15	U	P

ADMET properties:

None

Approvals:

Date	Agency	Company	Orphan
April 17, 1980	FDA	NOVARTIS

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Postpartum haemorrhage	459.48	100.39	59	387	311	2357328
Exposure during pregnancy	322.30	100.39	82	364	25137	2332502
Maternal exposure during pregnancy	252.29	100.39	61	385	14802	2342837
Hypotension	205.08	100.39	61	385	32375	2325264
Drug ineffective	174.13	100.39	72	374	101552	2256087
Uterine atony	171.54	100.39	21	425	65	2357574
Electrocardiogram ST segment depression	168.38	100.39	26	420	556	2357083
Caesarean section	129.03	100.39	28	418	4053	2353586
Maternal exposure during delivery	122.93	100.39	17	429	160	2357479
Pulmonary oedema	107.56	100.39	27	419	7336	2350303

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event

Pharmacologic Action:

Source	Code	Description
ATC	G02AC01	GENITO URINARY SYSTEM AND SEX HORMONES OTHER GYNECOLOGICALS UTEROTONICS Ergot alkaloids and oxytocin incl. analogues, in combination
ATC	H01BB02	SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS PITUITARY AND HYPOTHALAMIC HORMONES AND ANALOGUES POSTERIOR PITUITARY LOBE HORMONES Oxytocin and analogues
FDA PE	N0000009705	Increased Uterine Smooth Muscle Contraction or Tone
FDA Chemical/Ingredient	N0000006473	Oxytocin
MeSH PA	D010120	Oxytocics
MeSH PA	D012102	Reproductive Control Agents
CHEBI has role	CHEBI:36063	oxytocic
CHEBI has role	CHEBI:35620	vasodilator agent

Drug Use (View source of the data)

Disease	Relation	SNOMED_ID	DOID
Postpartum hemorrhage	indication	47821001
Incomplete miscarriage	indication	156072005
Induction of labor	indication	236958009
Pregnancy with abortive outcome	indication	363681007
Placental Reserve Studies	off-label use
Multiple pregnancy	contraindication	16356006
Grand multipara	contraindication	18656007
Placenta previa	contraindication	36813001	DOID:11060
Hypertensive disorder	contraindication	38341003	DOID:10763
Fetal distress	contraindication	130955003
Deliveries by cesarean	contraindication	200144004
Finding of malposition of fetus	contraindication	289365005

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	9.65	acidic
pKa2	12.47	acidic
pKa3	12.94	acidic
pKa4	13.18	acidic
pKa5	13.47	acidic
pKa6	13.7	acidic
pKa7	13.89	acidic
pKa8	6.4	Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Bioact source	MoA source
Oxytocin receptor	GPCR	P30559	OXYR_HUMAN	AGONIST	Ki	9.10	CHEMBL	CHEMBL
Vasopressin V2 receptor	GPCR	P30518	V2R_HUMAN		EC50	6.10	WOMBAT-PK
Vasopressin V1b receptor	GPCR	P47901	V1BR_HUMAN		EC50	6.35	WOMBAT-PK
Vasopressin V1a receptor	GPCR	P37288	V1AR_HUMAN		EC50	6.91	WOMBAT-PK
Oxytocin-neurophysin 1	Secreted	P01178	NEU1_HUMAN				WOMBAT-PK
Vasopressin V2 receptor	GPCR		V2R_RAT		Ki	7.21	CHEMBL
Oxytocin receptor	GPCR		OXYR_RAT		Ki	9.05	CHEMBL
Vasopressin V1a receptor	GPCR		V1AR_RAT	AGONIST	Ki	6.10	IUPHAR

External reference:

ID	Source
4018039	VUID
N0000146381	NUI
C0030095	UMLSCUI
D00089	KEGG_DRUG
1JQS135EYN	UNII
1480	INN_ID
12369008	SNOMEDCT_US
4018039	VANDF
4537	MMSL
7824	RXNORM
112115002	SNOMEDCT_US
5223	MMSL
d00584	MMSL
001307	NDDF
CHEMBL395429	ChEMBL_ID
DB00107	DRUGBANK_ID
CHEBI:7872	CHEBI
D010121	MESH_DESCRIPTOR_UI
439302	PUBCHEM_CID
2174	IUPHAR_LIGAND_ID

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Oxytocin	HUMAN PRESCRIPTION DRUG LABEL	1	0143-9742	INJECTION	10 [USP'U]	INTRAMUSCULAR	ANDA	12 sections
Oxytocin	HUMAN PRESCRIPTION DRUG LABEL	1	0143-9743	INJECTION	10 [USP'U]	INTRAMUSCULAR	ANDA	12 sections
Oxytocin	HUMAN PRESCRIPTION DRUG LABEL	1	0641-6114	INJECTION	10 [USP'U]	INTRAMUSCULAR	NDA	12 sections
Oxytocin	HUMAN PRESCRIPTION DRUG LABEL	1	0641-6115	INJECTION	10 [USP'U]	INTRAMUSCULAR	NDA	12 sections
Pitocin	HUMAN PRESCRIPTION DRUG LABEL	1	42023-116	INJECTION	10 [iU]	INTRAVENOUS	NDA	13 sections
Pitocin	HUMAN PRESCRIPTION DRUG LABEL	1	42023-130	INJECTION	10 [iU]	INTRAVENOUS	NDA	13 sections
Oxytocin	HUMAN PRESCRIPTION DRUG LABEL	1	52533-048	INJECTION, SOLUTION	10 [USP'U]	INTRAVENOUS	unapproved drug other
Oxytocin	HUMAN PRESCRIPTION DRUG LABEL	1	52533-051	INJECTION, SOLUTION	2 [USP'U]	INTRAVENOUS	unapproved drug other
Oxytocin	HUMAN PRESCRIPTION DRUG LABEL	1	52533-054	INJECTION, SOLUTION	30 [USP'U]	INTRAVENOUS	unapproved drug other
Oxytocin	HUMAN PRESCRIPTION DRUG LABEL	1	52533-055	INJECTION, SOLUTION	30 [USP'U]	INTRAVENOUS	unapproved drug other
Oxytocin	HUMAN PRESCRIPTION DRUG LABEL	1	52533-056	INJECTION, SOLUTION	30 [USP'U]	INTRAVENOUS	unapproved drug other
Oxytocin	HUMAN PRESCRIPTION DRUG LABEL	1	52533-105	INJECTION, SOLUTION	2 [USP'U]	INTRAVENOUS	unapproved drug other
Oxytocin	HUMAN PRESCRIPTION DRUG LABEL	1	52533-170	INJECTION, SOLUTION	30 [USP'U]	INTRAVENOUS	unapproved drug other
Oxytocin	HUMAN PRESCRIPTION DRUG LABEL	1	52533-233	INJECTION, SOLUTION	20 [USP'U]	INTRAVENOUS	unapproved drug other
Oxytocin	HUMAN PRESCRIPTION DRUG LABEL	1	52533-234	INJECTION, SOLUTION	30 [USP'U]	INTRAVENOUS	unapproved drug other
Oxytocin	HUMAN PRESCRIPTION DRUG LABEL	1	55154-9356	INJECTION, SOLUTION	10 [USP'U]	INTRAVENOUS	NDA	12 sections
Oxytocin	HUMAN PRESCRIPTION DRUG LABEL	1	55154-9577	INJECTION, SOLUTION	10 [USP'U]	INTRAVENOUS	NDA	12 sections
Oxytocin	HUMAN PRESCRIPTION DRUG LABEL	1	63323-012	INJECTION, SOLUTION	10 [USP'U]	INTRAVENOUS	NDA	12 sections